An advisory panel of the US Food and Drug Administration has voted not to recommend approval of canakinumab for the treatment of gouty arthritis attacks in patients who cannot get relief from NSAIDS, according to the drug’s sponsor, Novartis. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy